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Zearalenone  (ZEA)  is a secondary  fungal  metabolite  produced  mainly  by  a Fusarium
graminearum. To  clarify  the  toxicokinetics,  and  residues  of ZEA  and  its major  metabolites
-zearalenol  (-ZOL)  and -zearalenol  (-ZOL)  in  chickens,  ZEA  was  then  administered
intravenously  (iv)  or  orally  (po)  to  broiler  chickens  at a dosage  of 1.2  mg/kg  body  weight.
The  concentrations  of  ZEA,  -ZOL  and  -ZOL  in  the  plasma  and  various  tissues  were  quan-
tiﬁed  using  LC–MS/MS.  The  plasma  concentrations  of  ZEA  were  measurable  up  to 2 h after
iv  and  po administration,  and  the concentrations  of  -ZOL  and  -ZOL  were  detected  up
to  4 h  after  both  types  of  administration.  A  two-compartment  model  was  developed  to
describe  the  toxicokinetic  of  ZEA  in  broilers.  The  values  of t1/2 and  Vd were  1.36  ±  0.29  h-Zearalenol
-Zearalenol
oxicokinetics
esidues
roilers
and  6.40  ± 0.89  l/kg,  respectively.  The  absolute  oral  bioavailability  was  29.66  ± 5.6%. ZEA,
-ZOL  and -ZOL  were  measurable  in  the  vital  organs  after  po  administration.  These  results
suggest  that  ZEA  is  absorbed  from  the  gastrointestinal  tract  and  it has  ability  to  penetrate
into  the  various  tissues  of broiler  chickens.
s.  Publ
Y-NC-N©  2015  The  Author
the  CC  B
. Introduction
Zearalenone (ZEA), 6-(10-hydroxy-6-oxo-trans-1-
ndecenyl)--resorcyclic acid lactone, is a myco-estrogen
ith non-steroidal chemical structure produced by a vari-
ty of Fusarium fungi mainly by Fusarium graminearum.
ontamination of ZEA in various agricultural crops has
een observed worldwide especially in maize, wheat, oat
nd barley [13,21,27]. The most important toxic effect
f ZEA is its estrogenic effect, which induces impaired
ertility and abnormal fetal development in farm ani-
als [4]. Several publications reported that ZEA induced
epatocarcinogenesis, nephropathy and hematotoxicity in
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rodents and milk reduction in cows [1,14,18,26]. Regarding
the animal susceptibility to the toxic effects of ZEA, pigs
are the most susceptible to the estrogenic effects of ZEA
[2,6]. Thereafter, the contribution of the fate of ZEA to
the susceptibility difference is unknown, because it has
extensively been examined in pigs but not in other animals
[2,29].
The liver is the major organ responsible for metabolism
of ZEA to at least ﬁve stereoisomeric metabolites including
-zearalenol (-ZOL), -zearalenol (-ZOL), -zearalanol
(-ZAL), -zearalanol (-ZAL) and zearalanone (ZAN) [17].
These metabolites are also produced by the fungi and con-
taminate crops such as corn stems [3] and rice [22]. In
addition, recent report has shown the occurrence of - and
-zearalenol in corn by-product, corn silage and soy meal
[23]. Among these metabolites, -zearalenol is a major
hepatic metabolite of ZEA in various species especially rats
and ruminants [10,17]. The estrogenic activity of -ZOL is
cess article under the CC BY-NC-ND license (http://creativecommons.org/
352 K. Buranatragool et al. / ToxicologyFig. 1. Chemical structures of zearalenone (a), -zearalenol (b) and -
zearalenol (c).
3–100 times higher than that of ZEA [3,9,11,16,28]. The
results of three different bioassays using estrogen receptor
gene activation revealed that -zearalenol has 17 times as
strong as -ethinyl oestradiol [12]. Consequently, -ZOL
was found to cause reproductive dysfunctions in domestic
livestock [6] (Fig. 1).
The toxicokinetics and the corresponding tissue
residues of ZEA have been studied in livestock, but limited
information is available for broilers particularly, tissue
residues in broiler chickens. Recently, Osselaere et al. [20]
have reported the toxicokinetic characteristics of ZEA after
intravenous administration however, the information on
oral bioavailability, tissue residues and metabolism of ZEA
are not available in broiler chickens. Adequate information
on the disposition and the residue depletion of ZEA is also
needed to evaluate possible differences in toxicity among
species. Thus, we studied the fate, the residues and the
metabolites of ZEA in broilers, based on the pharmacoki-
netic parameters and toxin depletion observed in various
tissues.
2. Materials and methods2.1. Toxins and chemicals
ZEA, -ZOL and -ZOL were purchased from Wako
Chemical Co. (Tokyo, Japan). Other reagents and chemicals Reports 2 (2015) 351–356
of an analytical grade were purchased from Sigma Chemical
Co. (St. Louis, MO,  USA). Puriﬁed water was  produced using
the Milli-Q water puriﬁcation system from Millipore, Inc.
(Bedford, MA,  USA). ZEA was  dissolved with 10% dimethyl
sulfoxide (DMSO, Wako Pure Chemical Industry Ltd., Tokyo,
Japan) in physiologic saline to the ﬁnal concentration of
4 mg/ml  for administration.
2.2. Animals
Thirty-ﬁve 3-week-old female broilers (average weight
1.56 ± 2.32 kg) were obtained from Commercial chicken
farm (CP Group of companies, Saraburi Province, Thailand).
The experimental animals were housed in individual
stainless-steel cages at the Laboratory Animal Facility, Fac-
ulty of Veterinary Medicine, Kasetsart University and they
were acclimatized to the environment for 1 wk. The ani-
mals were fed with a commercial diet and drinking water
ad libitum. All experimental procedures carried out on the
animals in this study were ethically approved by the Ani-
mal  Ethics Research Committee of the Faculty of Veterinary
Medicine, Kasetsart University.
2.3. Experimental design for toxicokinetic study
Ten broiler chickens were weighed and then divided
into two groups (n = 5). After overnight fasting, each group
was  administered ZEA intravenously (iv) or orally (po) at a
dosage of 1.2 mg/kg bw. In this study, the dosage of ZEA was
determined based on the results of preliminary study infor-
mation. From our preliminary study, two dosages of ZEA at
0.6 and 1.2 mg/kg bw were examined in broiler chickens,
we found that the dosage of 1.2 mg/kg bw of ZEA was no
adverse effects observed. The level of ZEA and its metabo-
lites was detected more clearly than the lower dosage.
Taken together, this dosage was similar to the studies in
pigs and goats [8,15]. Blood samples were collected from
the wing veins of each animal with heparinized syringes
at 0, 5, 15 and 30 min  and at 1, 2, 4, 8 and 12 h after ZEA
administration. The plasma was separated by centrifuga-
tion (1968 × g) for 15 min. All of the plasma was  frozen at
−20 ◦C until analysis.
2.4. Experimental design for tissue residue study
Twenty-ﬁve broilers were administered ZEA orally at
a dosage of 1.2 mg/kg of bw.  The remaining ﬁve broilers
served as controls and were orally administered DMSO
in 0.9% physiologic saline. Animals were sacriﬁced with
thiopentone sodium at a dosage of 20 mg/kg bw by iv
administration. Tissue samples, including liver, kidney,
muscle, intestine and excreta, were collected at 1, 3, 9 and
12 h after po administration (n = 5), respectively. All sam-
ples were frozen at −20 ◦C until analysis.
2.5. Extraction and clean-up procedureThe extraction method of ZEA and its metabolites in
plasma, tissues and excreta was  performed as described
previously [25]. Brieﬂy, 1 ml  of broiler plasma was mixed
with 6 ml  of ammonium acetate buffer (pH 4.8); it was
icology 
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elimination rate constant, and K12 and K21 were the micro-
rate constants. The absolute oral bioavailability (F) wasK. Buranatragool et al. / Tox
hen incubated for 15 h at 37 ◦C with 25 l of glu-
uronidase/arylsulfatase solution before adding 6 ml  of
hosphate buffer (PB, pH 7.4). The sample was then
entrifuged at 1926 × g for 15 min. The supernatant was
pplied to immune-afﬁnity column (IAC, Easi-Extract®
earalenone, R-Biopharm Rhone Ltd., Dmstadt, Germany)
fter the IAC was preconditioned with 10 ml  of PB. The IAC
as rinsed with 15 ml  of puriﬁed water. The analytes were
luted with 1.5 ml  of acetonitrile and evaporated to dryness
nder a nitrogen stream at 40 ◦C on a heating block. The
esidue was redissolved with 150 l of water–methanol
ixtures (50:50, v/v) and then analyzed by liquid chro-
atography tandem mass spectrometry (LC–MS/MS).
A quantity of 1 g of tissue sample, ground and dried at
5 ◦C was extracted in 50 ml  of water-methanol (50/50, v/v)
or 60 min. The sample was then centrifuged at 1926 × g
or 10 min. A 20 ml  of supernatant was collected and
ixed with 40 ml  of buffer solution acetic acid-ammonium
cetate, pH 4.8, it was then incubated for 15 h at 37 ◦C
ith 80 l of a solution of glucuronidase/arylsulfatase and
djusted to pH 4.0 with glacial acetic acid. The solution was
oaded into a Chromabond C18 column (Fisher Scientiﬁc
td., UK) after it was preconditioned with 10 ml  of methanol
nd 10 ml  of Milli-Q water. Thereafter, the columns loaded
ith the sample were rinsed with 5 ml  of Milli-Q water and
 ml  of a methanol–water (30:70, v/v) mixture. The ana-
ytes were eluted with 1.25 ml  of methanol. The eluate was
ixed with 15 ml  of PB and applied to immune-afﬁnity col-
mn  (IAC, Easi-Extract® Zearalenone, R-Biopharm Rhone
td., Dmstadt, Germany) after the IAC was preconditioned
ith 10 ml  of PB. The IAC was rinsed with 15 ml  of puriﬁed
ater. The analytes were eluted with 1.5 ml  of acetoni-
rile and evaporated to dryness under a nitrogen stream
t 40 ◦C on a heating block. The residue was redissolved
ith 150 l of water–methanol mixtures (50:50, v/v) and
hen analyzed by LC–MS/MS.
Two grams of excreta were extracted with 40 ml  of
ethanol–water (50:50, v/v). After centrifugation, 20 ml  of
upernatant was mixed with 40 ml  of 0.05 M ammonium
cetate buffer pH 4.8. This solution was incubated for 15 h
t 37 ◦C with 80 l of glucuronidase/arylsulfatase solution.
ll the following steps were performed as described above
or clean-up of tissue samples. The eluate was evaporated
o dryness under a nitrogen stream. The residue was redis-
olved in 250 l of water–methanol mixtures (50:50, v/v)
nd then analyzed by LC–MS/MS.
.6. LC parameters
The LC analysis was performed using an Agilent
200 series system consisting of a binary high-pressure
radient pump, a vacuum solvent degassing unit, an
utomatic sample injector and a column thermostat (Agi-
ent Technologies, Waldbronn, Germany). Separation was
chieved by a Poroshell 120 EC-C18 column (2.7 m,
.0 mm × 50 mm)  (Agilent Technologies, Palo, Alto, CA,
SA) The column was maintained at a temperature of 45 ◦C.
he LC mobile phase program consisted of a binary gradi-
nt of the 0.1% acetic acid in water (mobile phase A) and
cetonitrile (mobile phase B). The composition started out
t 30% mobile phase B and increased linearly to 70% mobileReports 2 (2015) 351–356 353
phase B by 6.4 min. The mobile phase then returned to 30%
acetonitrile by 7 min, and the column was equilibrated for
3 min. The ﬂow rate was 200 l/min; the injection volume
was 10 l.
2.7. MS parameters
Mass spectrometry was  performed using an Agi-
lent Technologies 6460 triple quard mass spectrometer
equipped with an electrospray ionization (ESI) source and
Agilent MassHunter Workstation Software version 1.2. ESI-
MS/MS  was operated at unit mass resolution in multiple
reaction monitoring (MRM)  negative ion mode with the fol-
lowing settings: nebulizer gas pressure (NEB): 45 psi, gas
ﬂow 5.0 l/ml, gas temperature 300 ◦C, and Capillary volt-
age: −3500 V. The following transitions were used: ZEA:
m/z 317.1 > 175 and 317.1 > 131, -ZOL: 319.15 > 275.1, and
for -ZOL: 319.15 > 275.1.
2.8. Fortiﬁcation procedure
To evaluate recovery, ZEA and its metabolites -
ZOL and -ZOL were added to samples of blank
plasma and tissues to yield ﬁnal ZEA, -ZOL and -
ZOL concentrations of 1, 5, 10, 50, 100, and 200 ng/ml
(ng/g), respectively. The spiked samples were then
analyzed in duplicate as described in the extrac-
tion/cleanup procedures. The mean (±SD) recoveries were
follows; ZEA: 95.16 ± 4.61%, 84.56 ± 3.21%, 86.27 ± 5.18%,
83.63 ± 2.85%, 92.12 ± 3.52 and 101.63 ± 3.36%, -ZOL:
90.22 ± 5.11%, 82.05 ± 4.15%, 88.13 ± 4.68%, 85.19 ± 4.06%,
93.15 ± 4.13 and 102.18 ± 4.24%, -ZOL: 91.21 ± 4.11%,
85 ± 4.13%, 87.35 ± 4.26%, 84.24 ± 3.16%, 94.42 ± 4.12 and
103.61 ± 3.12% in the plasma, liver, kidney, muscle, small
intestine and excreta, respectively. The limit of detection
(LOD) of ZEA, -ZOL and -ZOL was  1 ng/ml (ng/g) in piglet
plasma, excreta and various tissues. The limit of quantiﬁca-
tion of ZEA, -ZOL and -ZOL was 2–2.5 ng/ml (ng/g). The
r2 value of the ZEA, -ZOL and -ZOL calibration curves
was 0.992–0.996. The precision and accuracy indicated the
method was repeatable. The intra- and inter-day precisions
were <12%.
2.9. Toxicokinetic parameter calculations
The concentration of ZEA in experimental broiler chick-
ens with respect to time was  pharmacokinetically analyzed
using a two-compartment model with the PK Solutions
2.0TM Program (Summit Research Services, Montrose, CO,
USA), where C0p was the peak concentration at initial time,
AUC0–∞ was  the area under the curve, t1/2 was the elimi-
nation half-life, t1/2 was the distribution half-life, Vd(area)
was the volume of distribution, Cl was  the plasma clear-
ance, MRT was  the mean residence time, Kel was thecalculated using the following equation:
(%)F (po) = (AUC po)
(AUC iv)
× 100
354 K. Buranatragool et al. / Toxicology Reports 2 (2015) 351–356
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Fig. 2. Mean values (±SD) of zearalenone (ZEA), -zearalenol (-ZOL)
Table 1
Mean ± SD value of the toxicokinetic parameters of zearalenone (ZEA) fol-
lowing a single intravenous or oral administration at a dosage of 1.2 mg/kg
bw in broiler chickens (n = 5).
Toxicokinetic parameters (unit) Value
Intravenous administration
Kel (h) 0.53 ± 0.11
K12 (h−1) 1.33 ± 0.10
K21 (h−1) 0.68 ± 0.17
t1/2 (h) 0.10 ± 0.01
t1/2 (h) 1.36 ± 0.29
CL  (L/h/kg) 0.34 ± 0.03
Vd (L/kg) 6.40 ± 0.89
MRT  (h) 2.1 ± 0.41
Oral administration
Cmax (ng/ml) 15.9 ± 4.5
Tmax (min) 15.0 ± 0.0
Fpo (%) 29.66 ± 5.6
Kel, elimination rate constant; K12, K21, micro-rate constants; t1/2 , distri-
and -zearalenol (-ZOL) concentrations in plasma broiler chickens after
intravenous injection of ZEA at a dosage of 1.2 mg/kg BW;  () -ZOL, ()
-ZOL, and () ZEA (n = 5).
2.10. Statistical analysis
The plasma concentration curves and tissue residues of
ZEA, -ZOL and -ZOL are shown as the mean (±SD, n = 5) of
the values for the broiler chickens sampled. Toxicokinetic
parameters are also shown as the mean (±SD, n = 5).
3. Results
3.1. Plasma concentration and toxicokinetic parameters
The determination of ZEA, -ZOL and -ZOL concen-
trations showed that they were detectable in the plasma
of broiler chickens following a single iv or po adminis-
tration of ZEA. The semi-logarithmic plots of the mean
(±SD) plasma concentration–time curves of ZEA, - ZOL
and -ZOL at a dosage of 1.2 mg/kg bw in broiler chick-
ens following iv and po administrations are shown in
Figs. 2 and 3, respectively. ZEA was measurable from
5 min  to 2 h, whereas -ZOL and -ZOL were detectable
from 5 min  to 4 h after iv and po administration of ZEA,
respectively. The plasma proﬁle displayed a rapid decrease
Fig. 3. Mean values (±SD) of zearalenone (ZEA), -zearalenol (-ZOL) and
-zearalenol (-ZOL) concentrations in plasma broiler chickens after oral
administration of ZEA at a dosage of 1.2 mg/kg BW;  () -ZOL, () -ZOL,
and () ZEA (n = 5).bution half-life; t1/2 , elimination half-life; CL,  clearance; Vd, volume of
distribution; MRT, mean residence time; Cmax, maximum concentration;
Tmax, time at maximum concentration; Fpo, oral bioavailability.
in the ZEA concentration with time in both groups, as
was  to be expected following iv administration. The ZEA
disposition ﬁt an open 2-compartment pharmacokinetic
model because ZEA concentration declined rapidly in a
biphasic pattern, indicating fast distribution and elimina-
tion (Fig. 2) Following iv administration, the values for the
t1/2, Vd, Cl, and MRT  were 1.36 ± 0.29 h, 6.40 ± 0.89 l/kg,
0.34 ± 0.03 l/h/kg and 2.10 ± 0.41 h, respectively. The mean
(±SD) toxicokinetic parameters of ZEA in plasma after
a single iv administration are summarized in Table 1.
The maximum plasma concentration (Cmax) of ZEA was
15.90 ± 4.50 ng/ml at 15 min after po administration. The
absolute oral bioavailability was  29.66%. ZEA, -ZOL and
-ZOL were also detected in excreta up to 12 h following
po administration (Table 1).
The LC–MS/MS proﬁle for various tissues, including the
liver, kidney, muscle and small intestine, showed that ZEA
was  measurable up to 1 h in liver, kidney and small intes-
tine, whereas it was  not detectable in muscle of broiler
chickens after po administration (Table 2). The maximum
level of ZEA was 114.7 ± 13.1 ng/g at 1 h in small intestine
after po administration. -ZOL and -ZOL were detectable
up to 12 h in liver, kidney and small intestine, whereas they
were detectable up to 1 h in muscle after po administration.
All of ZEA, -ZOL and -ZOL were measurable up to 12 h in
excreta of broiler chickens (Table 2).
4. Discussion
To date, there are several publications for toxicoki-
netics and metabolism of ZEA in pigs and goats by single
bolus of ZEA at 1 and 1.2 mg/kg bw, respectively. In this
study, an intravenous or oral administration of ZEA at
1.2 mg/kg bw,  the dose similar to their studies, we  used to
compare the fate of ZEA metabolism among broilers, goats
and pigs [8,15]. The present study used LC–MS/MS with
electrospray ionization to determine the concentrations
of ZEA and its active metabolites -ZOL and -ZOL in
the plasma, excreta and various tissues following iv or
K. Buranatragool et al. / Toxicology 
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po administration in broiler chickens. In the present
study, no adverse effects were observed following the
administration of ZEA in broiler chickens. Following iv
administration, the t1/2 indicates the overall rate of
elimination and allows the prediction of ZEA accumulation
with a value for ZEA of 1.36 h in broiler chickens. The mean
residence time was  2.10 h after iv administration. The ZEA
appears to have been excreted rapidly in broiler chickens.
The t1/2 of ZEA obtained in broilers of the present study
was shorter than in pigs (2.63 h) [5] and goats (28.58 h)
[8]. The Vd of ZEA in broiler chickens was  6.40 l/kg after
iv administration. These results suggested that ZEA has
penetrated to various tissues, although it appears to have
been excreted rapidly after iv administration in broiler
chickens. Regarding the values of Vd and Cl of ZEA in other
animal species, they were 10.48 l/kg and 0.048 l/min/kg in
pigs [5], whereas they were 7.32 l/kg and 0.003 l/min/kg in
goats [8], respectively. Thus, the difference in susceptibility
to the estrogenic effects of ZEA between ruminant and
non-ruminant species cannot be explained by circulating
ZEA and its metabolites [2,6]. Furthermore, a large pro-
portion of -ZOL and -ZOL was  found in the plasma of
broiler chickens. -ZOL and -ZOL were detectable in the
plasma from 5 min  to 4 h after iv administration of ZEA.
The results suggested that ZEA was  transformed rapidly
into -ZOL and -ZOL in plasma of broiler chickens.
Following oral administration, a large proportion of ZEA
was changed into -ZOL and -ZOL in the plasma and
various tissues of broiler chickens following ZEA adminis-
tration, indicating that ZEA was absorbed and metabolized
rapidly. In addition, -ZOL and -ZOL were detectable up
to 12 h in liver, kidney and small intestine, whereas they
were detectable up to 1 h in muscle after po administration.
The absolute oral bioavailability of ZEA was 29.66 ± 5.6%;
it was  higher in broilers than in rats (2.7%) [24]. The level
of -ZOL and -ZOL in each tissue followed as small intes-
tine > liver > kidney and muscle. The proportion of -ZOL
was higher than -ZOL in broiler chickens. Accordingly,
these ﬁndings are in general agreement with other stud-
ies where -ZOL was  reported to be the major metabolite
of ZEA [2,5,7,19,29]. This also indicates that ZEA has the
ability to penetrate into the various tissues of broilers as
well. The LC–MS/MS proﬁle of excreta showed a large pro-
portion of -ZOL and -ZOL after the administration of ZEA
in broiler chickens, however the proportion of -ZOL was
higher than -ZOL. These ﬁndings clearly show that ZEA
is excreted largely in the form of -ZOL in the excreta of
broiler chickens.
5. Conclusion
The study demonstrated here is the toxicokinetic pro-
ﬁle of ZEA. ZEA and its active metabolites -ZOL and -ZOL
were measurable in plasma, excreta and various tissues of
broiler chickens after a single iv or po administration of ZEA.
-ZOL appears to be the major metabolite of ZEA in broiler
chickens. Based on the toxicokinetic information, ZEA is
absorbed rapidly from the gastrointestinal tract and exten-
sively penetrates into various tissues. ZEA can be excreted
largely in the form of -ZOL in the excreta of broiler chick-
ens.
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